Evidence map›Paper›PMID 30828563›Full record

ArticleFrontiers in oncology2019

Activation of Epithelial-Mesenchymal Transition and Altered β-Catenin Signaling in a Novel Indian Colorectal Carcinoma Cell Line.

Sanghamitra Mylavarapu, Harsh Kumar, Smita Kumari, L S Sravanthi, Misti Jain, Aninda Basu, Manjusha Biswas, Sivaram V S Mylavarapu, Asmita Das, Monideepa Roy

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Sanghamitra MylavarapuInvictus Oncology Pvt. Ltd., New Delhi, India.
Harsh KumarRegional Centre for Biotechnology, Faridabad, India.
Smita KumariInvictus Oncology Pvt. Ltd., New Delhi, India.
L S SravanthiIndia Innovation Research Center, New Delhi, India.
Misti JainDivision of Cancer Biology, MITRARxDx India Pvt. Ltd., Bangalore, India.
Aninda BasuDivision of Cancer Biology, MITRARxDx India Pvt. Ltd., Bangalore, India.
Manjusha BiswasDepartment of Molecular Pathology, MITRARxDx India Pvt. Ltd., Bangalore, India.
Sivaram V S MylavarapuRegional Centre for Biotechnology, Faridabad, India.
Asmita DasDepartment of Biotechnology, Delhi Technological University, New Delhi, India.
Monideepa RoyInvictus Oncology Pvt. Ltd., New Delhi, India.
Department of Biotechnology · INInnovation Center Denmark · INDelhi Technological University · INRegional Centre for Biotechnology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is the third major cause of cancer-related mortality worldwide. The upward trend in incidence and mortality rates, poor sensitivity to conventional therapies and a dearth of early diagnostic parameters pose a huge challenge in the management of colorectal cancer in India. Due to the high level of genetic diversity present in the Indian population, unraveling the genetic contributions toward pathogenesis is key for understanding the etiology of colorectal cancer and in reversing this trend. We have established a novel cell line, MBC02, from an Indian colorectal cancer patient and have carried out extensive molecular characterization to unravel the pathological alterations in this cell line. In-depth molecular analysis of MBC02 revealed suppression of E-cadherin expression, concomitant with overexpression of EMT related molecules, which manifested in the form of highly migratory and invasive cells. Loss of membrane-tethered E-cadherin released β-catenin from the adherens junction resulting in its cytoplasmic and nuclear accumulation and consequently, upregulation of

Indexed as

colorectal cancerEMTmitotic defectssignalingβ-catenin

Identifiers

PMID30828563
PMCPMC6385509
OpenAlexW2912530485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.